This video reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes.
In this video, Olatoyosi Odenike, MD, of the University of Chicago Medicine, reviews novel treatment approaches in the management of higher-risk myelodysplastic syndromes (MDS).
Odenike gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations
July 30th 2025Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.